Heterogeneity among RIP‐Tag2 insulinomas allows vascular endothelial growth factor‐A independent tumor expansion as revealed by studies in Shb mutant mice: Implications for tumor angiogenesis
- 31 January 2012
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 6 (3), 333-346
- https://doi.org/10.1016/j.molonc.2012.01.006
Abstract
The Shb adapter protein is a signaling intermediate that operates downstream of vascular endothelial growth factor receptor-2 (VEGFR-2) in endothelial cells. The Shb knockout mouse displays a dysfunctional microvasculature and impaired growth of subcutaneously implanted tumor cells. We decided to investigate tumor growth and angiogenesis in the absence of Shb in an inheritable tumor model, the RIP-Tag2 mouse, which produces insulinomas in a manner highly dependent on de nova angiogenesis. We observed a reduced tumor incidence and burden in both RIP-Tag2 Shb-/- and RIP-Tag2 Shb+/- mice. This correlated with a reduced microvascular density, measured as a percentage of insulinoma area positive for CD31 staining, and altered vascular morphology. However, treatment with a VEGFA blocking antibody was without effect on the Shb mutant tumor volume whereas it significantly inhibited tumor volume in the wild-type mice, suggesting that in mice with reduced Shb expression tumor angiogenesis was primarily sustained by VEGF-A independent pathway(s). This notion was further substantiated by gene expression analysis of angiogenic markers showing reduced VEGF-A expression in Shb-deficient tumors. Considerable heterogeneity with respect to the gene expression profiles of other angiogenic markers and the signal-transduction characteristics was observed between different tumors, suggesting that multiple "rescue" pathways could be operating. The numbers of invasive tumors or metastases were unchanged in the Shb mutant. It is concluded that the Shb mutant background reduces tumor frequency by chronically suppressing VEGF-A dependent angiogenesis. However, VEGF-A independent angiogenesis supports a significant degree of tumor expansion in Shb-deficient mice, indicating heterogeneity in the mechanisms by which tumor expansion is promoted. Interference with Shb signaling may provide novel means for future cancer therapy. (C) 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.Keywords
Funding Information
- Swedish Cancer Fund (100494)
- Swedish Research Council (68X-10822)
- Swedish Diabetes Association (2009-006)
- Wallenberg Foundation
- Family Ernfors Fund
This publication has 38 references indexed in Scilit:
- Shb deficient mice display an augmented TH2 response in peripheral CD4+ T cellsBMC Immunology, 2011
- Conversion of vascular endothelial cells into multipotent stem-like cellsNature Medicine, 2010
- Genetic Deletion of the Desmosomal Component Desmoplakin Promotes Tumor Microinvasion in a Mouse Model of Pancreatic Neuroendocrine CarcinogenesisPLoS Genetics, 2010
- The Src Homology 2 Domain-Containing Adapter Protein B (SHB) Regulates Mouse Oocyte MaturationPLOS ONE, 2010
- Micro computed tomography for vascular explorationJournal of Angiogenesis Research, 2010
- Increased Hsp70 expression attenuates cytokine-induced cell death in islets of Langerhans from Shb knockout miceBiochemical and Biophysical Research Communications, 2009
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant MetastasisCancer Cell, 2009
- Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter proteinBMC Cancer, 2007
- Consequences of Shb and c-Abl interactions for cell death in response to various stress stimuliExperimental Cell Research, 2007
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989